Inpatient Admissions Predict Peri-Op Risk in Lumbar Fusion

Share this content:
Inpatient Admissions Predict Peri-Op Risk in Lumbar Fusion
Inpatient Admissions Predict Peri-Op Risk in Lumbar Fusion

MONDAY, Dec. 22, 2014 (HealthDay News) -- For patients undergoing posterior lumbar fusion, inpatient admissions in the prior year are associated with increased complication rate, length of stay, and total charges, according to a study published in the Dec. 15 issue of Spine.

Ananth Eleswarapu, M.D., from the University of Chicago Medical Center, and colleagues examined risk factors for increased complication rate, length of stay, and hospital charges for patients undergoing posterior lumbar fusion. Data were collected from a quality improvement data set for 462 patients.

The researchers found that the only variable significantly associated with increased complication rate was history of more than one admission in the prior year (odds ratio, 10.56; P < 0.0001). Increased length of stay correlated with history of more than one admission in the prior year (P < 0.0001), operative duration of more than five hours (P = 0.008), and American Society of Anesthesiologists physical status classification of 3 or greater (P = 0.01). Increased total charges were seen in association with history of more than one admission in the prior year, fusion of four or more levels, and operative duration of more than five hours (all P < 0.0001).

"The number of inpatient admissions in the prior year was found to be a more powerful predictor of perioperative risk after lumbar fusion than metrics evaluated in prior studies, such as age, body mass index, and comorbidities," the authors write.

Relevant financial activities outside the submitted work were disclosed: board membership, consultancy, royalties, stocks, grants, employment.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths